SCHEMBL7216560

SCHEMBL7216560

[CH2]CCCC(C)(C)C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACLY P53396 1/20 0.54
ACACB O00763 1/20 0.52
ACACA Q13085 1/20 0.52
PPARA Q07869 9/20 0.41
TBXAS1 P24557 4/20 0.40
TSHR P16473 2/20 0.39
TTR P02766 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C8 P10632 1/20 0.39
CHRM1 P11229 1/20 0.39
CYP2C9 P11712 1/20 0.39
ADRA1A P35348 1/20 0.39
PPARG P37231 1/20 0.39
HTR2B P41595 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
SLCO1B3 Q9NPD5 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
CISD1 Q9NZ45 1/20 0.39
SLCO1B1 Q9Y6L6 1/20 0.39
GUCY1A1 Q02108 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL874273 0.91 ACLY (0.61) ACLYACACBACACAPPARATBXAS1
SCHEMBL127297 0.84
SCHEMBL7222208 0.84 ACLY (0.70) ACLYACACBACACAPPARATBXAS1
SCHEMBL2784372 0.84 ACLY (0.62) ACLYACACBACACAPPARATBXAS1
SCHEMBL1836313 0.81 ACLY (0.74) ACLYACACBACACAPPARATBXAS1
SCHEMBL1832600 0.81 ACLY (0.74) ACLYACACBACACAPPARATBXAS1
SCHEMBL5528331 0.81 ACLY (0.74) ACLYACACBACACAPPARATBXAS1
SCHEMBL4190226 0.81 ACLY (0.74) ACLYACACBACACAPPARATBXAS1
SCHEMBL20474799 0.81 ACLY (0.74) ACLYACACBACACAPPARATBXAS1
SCHEMBL9177458 0.81 ACLY (0.74) ACLYACACBACACAPPARATBXAS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6503898-B1 Administering 4,7-dibenzyl-5,6-dihydroxy-N,N*-di(m-aminobenzyl)--1,3-diazepin-2-one or salt to treat human immunodeficiency virus infection BRISTOL-MYERS SQUIBB PHARMA COMPANY 2003-01-07 US disclosed